Evidence map›Paper›PMID 24525232›Full record

Trial reportCancer cell2014

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Woonyoung Choi, Sima Porten, Seungchan Kim, Daniel Willis, Elizabeth R Plimack, Jean Hoffman-Censits, Beat Roth, Tiewei Cheng, Mai Tran, I-Ling Lee and 10 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04872036 (Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens), which is not on this map. Cited by 981 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
981citing papers in PubMed, 4 pooled it
118.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04872036 completednot on this map

Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens

TypeobservationalSponsorHellenic Cooperative Oncology GroupRan2000 to 2017Enrolled66ConditionsBladder Cancer
3 · Its place in the literature

Who cites it

981 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,717 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. TP53 mutation-biased CD8British journal of cancer · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

921 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Woonyoung ChoiDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sima PortenDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Seungchan KimComputational Biology Division, Translational Genomics Research Institute, 445N, Fifth Street, Phoenix, AZ 85004, USA.
Daniel WillisDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Elizabeth R PlimackDepartment of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA.
Jean Hoffman-CensitsDepartment of Medical Oncology, Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 700, Philadelphia, PA 19107, USA.
Beat RothDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tiewei ChengDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas-Graduate School of Biomedical Sciences (GSBS) at Houston, Houston, TX 77030, USA.
Mai TranDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas-Graduate School of Biomedical Sciences (GSBS) at Houston, Houston, TX 77030, USA.
I-Ling LeeDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jonathan MelquistDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jolanta BondarukDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tadeusz MajewskiDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shizhen ZhangDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shanna PretzschDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Keith BaggerlyDepartment of Bioinformatics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Arlene Siefker-RadtkeDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bogdan CzerniakDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Colin P N DinneyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
David J McConkeyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas-Graduate School of Biomedical Sciences (GSBS) at Houston, Houston, TX 77030, USA. Electronic address: dmcconke@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Houston · USFox Chase Cancer Center · USThomas Jefferson University Hospital · USTranslational Genomics Research Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
Aurora Kinase A as a Biomarker for the Detection of Bladder CancerR01CA151489 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CZERNIAK, BOGDAN A · 2010 to 2013
$1.6M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NCI NIH HHS P50 CA91846NCI NIH HHS R01 CA151489PHS HHS P30 016672
6 · The paper itself

Abstract

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. We discovered three molecular subtypes of MIBC that resembled established molecular subtypes of breast cancer. Basal MIBCs shared biomarkers with basal breast cancers and were characterized by p63 activation, squamous differentiation, and more aggressive disease at presentation. Luminal MIBCs contained features of active PPARγ and estrogen receptor transcription and were enriched with activating FGFR3 mutations and potential FGFR inhibitor sensitivity. p53-like MIBCs were consistently resistant to neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after therapy. Our observations have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBasal Cell CarcinomaBiomarkers, TumorBlotting, WesternCarcinoma, Squamous CellCell DifferentiationCell ProliferationCisplatinClinical Trials, Phase II as TopicCohort StudiesDoxorubicinDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansBiomarkers, TumorCisplatinDoxorubicinFGFR3 protein, humanMethotrexateMicroRNAsPPAR gammaReceptor, Fibroblast Growth Factor, Type 3Receptors, EstrogenRNA, MessengerTP53 protein, humanTumor Suppressor Protein p53Vinblastine

Identifiers

PMID24525232
PMCPMC4011497
OpenAlexW2033775272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.